Powered by Getro
Showing 446 companies
Biotechnology
DeepTech
Health
1 - 10
Series C+

10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.

23andMe
23andMe
27 jobs
Biotechnology
DeepTech
Health
201 - 1000

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Biotechnology
DeepTech
Design
Health
11 - 50
Series A

A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Abbott
Abbott
2,289 jobs
Biotechnology
DeepTech
Food
Health
Manufacturing
5001+

Abbott is engaged in pharmaceuticals and manufacturing healthcare products. It developed the first HIV blood-screening test. Its product portfolio includes Norvir, a treatment for HIV; Synthroid, a synthetic thyroid hormone; Depakote, an anticonvulsant drug; and Humira, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and more. Its medical tests and diagnostic instrument systems are manufactured for usage in hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, and more. Abbott also operates its product manufacturing segment known as Abbott Point-of-Care. It manufactures diagnostic products for blood analysis. It also provides cardiac assays to the emergency room. It currently has 90,000 employees and operates in over 130 countries. Abbott was established in 1888 by Chicago physician Wallace Calvin Abbott. It is based in Abbott Park, North Chicago, Illinois.

AbbVie
AbbVie
43 jobs
Biotechnology
DeepTech
Health
5001+

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.

Biotechnology
DeepTech
Health
201 - 1000

AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation.

AbSci
AbSci
5 jobs
Biotechnology
Data and Analytics
DeepTech
Health
Software
51 - 200

AbSci is a synthetic biology company that translates ideas into drugs with a platform technology that reinvents the biopharmaceutical drug discovery process. They custom engineer E. coli to create novel complex biologics in their full length format while simultaneously developing production cell lines. The company is deploying cutting-edge deep learning artificial intelligence to inform their designs, and every day we succeed in achieving things others have dismissed as impossible.

Biotechnology
Data and Analytics
DeepTech
Design
Health
51 - 200

Active Motif Chromeon provides innovative fluorescent reagents for Life Science research applications including several lines of fluorescent chromophores the Chromeo Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets, ideal for microscopy and plate-based assays. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while reatly reducing background. As alternative to organic dyes, a set of bright and biocompatible fluorescent nanoparticles is offered. They represent excellent tools for increasing the sensitivity of your assays.

Biotechnology
DeepTech
Health
201 - 1000

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

Biotechnology
Data and Analytics
DeepTech
Design
Health
51 - 200
Series B

Aera Therapeutics is a biotechnology company that uses its proprietary protein nanoparticle (PNP) delivery platform to help genetic medicines reach their full potential. Aera's platform, which is based on endogenous human proteins, is being developed to address the limitations of current delivery technologies and to extend the reach of genetic medicines to different tissues and applications, thereby benefiting more patients across a broader range of disease areas. In addition, Aera's licensed technology includes a therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.

Biotechnology
DeepTech
Manufacturing
1001 - 5000

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Life Sciences, CMC Biologics, and BIOMEVA GmbH. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan. AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, both mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression — including our proprietary CHEF1 Expression System for mammalian production. Our company DNA drives us to provide innovative solutions for clients to reach their goals and accelerate their projects, as well as facilitate approval and manage spending during the product lifecycle. AGC Biologics forges exceptionally strong partnerships with our clients, and we never lose sight of our commitment to deliver reliable and compliant drug substance supply, on time. Visit www.agcbio.com to learn why AGC Biologics is a World Leader in process development and contract manufacturing.